· Original article
Narsoplimab review leaves Omeros facing European access hurdles
The narsoplimab review ended in another negative CHMP opinion, while Omeros plans to end compassionate use and pursue reimbursed patient access.
FINANCEVELIX / News
Equities & companies · Page 38
Equities & companies
Listed companies, earnings, corporate developments and equity markets. Company and asset tags identify the subjects of a story.
Read the original source and publication date in each article.
Equities & companies
RSSResults: 1,580 · Page 38 / 132
· Original article
Truist earnings: Q3 adjusted profit rises as sales hit GAAP
Truist earnings show higher adjusted EPS in Q3 2026, but securities losses cut reported profit as the bank reshapes lending and returns capital.
· Original article
Citizens dividend rises 13% as buyback capacity expands
Citizens dividend rises to $0.52 per share after Q3 2026 results, while the bank expands buyback capacity to $1.95 billion despite a revenue miss.
· Original article
UBS relocation talks put London in focus amid Swiss reforms
UBS relocation discussions with the UK government put London in focus as Switzerland pursues tougher capital backing for foreign subsidiaries.
· Original article
CCL Products earnings call covers September-quarter FY27
CCL Products earnings call covered Q2 FY27 on October 16, 2026, but the available opening remarks contain no financial results or guidance.
· Original article
Intel stock falls to $95.37 ahead of October 29 earnings
Intel stock closed October 15 at $95.37, down 25.1% from September 24, as investors awaited earnings and an update on its foundry business.
· Original article
Doman results set for November 6, with analyst call to follow
Doman results for the third quarter of 2026 are due November 6 after market hours, followed by a November 9 analyst call with its CEO and CFO.
· Original article
Branded Call Display earns 2026 invention recognition
TransUnion’s Branded Call Display received 2026 invention recognition as the company reported more than 7 billion branded-call impressions.
· Original article
Royalty Pharma dividend set at $0.235 for fourth quarter
Royalty Pharma dividend of $0.235 per Class A share is payable December 10, 2026, with a November 13 record date for the fourth-quarter distribution.
· Original article
PBAM earnings rise annually but slip from prior quarter
PBAM earnings rose from a year earlier in Q3 2026, but higher expenses and credit provisions reduced profit from the previous quarter.
· Original article
Rett biomarker program at Niki featured in IRSF series
Niki’s Rett biomarker program features in an IRSF research series as its DiamiR subsidiary explores blood-based tools for tracking disease progression.
· Original article
Aduro results show cash boost and wider adjusted loss
Aduro results for fiscal Q1 2027 show C$65.7 million in cash after equity financing, while a non-cash gain masks a wider adjusted EBITDA loss.
Charts and market data by TradingView. Availability and delays vary by exchange.